Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FANCC
REST API REST API
Homo sapiens
FANCC is differentially expressed in 182 experiments: 82 organism parts: liver, cerebellum, ... (80 more);, 122 disease states: normal, acute promyelocytic leukemia, ... (120 more);, 47 cell types 186 cell lines 23 compound treatments and 62 other conditions.
Synonyms FACC, FAC, FA3
Orthologs FANCC (Gallus gallus)   fancc (Danio rerio)   Fancc (Mus musculus)   A5PJJ8_BOVIN (Bos taurus)   Fancc (Rattus norvegicus)   fancc (Xenopus laevis)   ENSCAFG00000023612 (Canis familiaris)   XM_843898.1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, nucleotide-excision repair, protein binding, DNA repair, cytoplasm, protein complex assembly, gamete generation, nucleus, germ cell development, chromatin, nucleoplasm, Fanconi anaemia nuclear complex, myeloid cell homeostasis, removal of superoxide radicals
InterPro Term Fanconi
UniProt Accession Q00597, B4E3W2, B1ALR7
Gene-Disease Assocation FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC, FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA
Search EB-eye ENSG00000158169
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, E-GEOD-4717, E-MTAB-62, ... (28 experiments)

Factor Value U/D Experiments
HT1080
2
E-GEOD-20089, E-MTAB-37
MCF-7
2
E-GEOD-20081, E-GEOD-5823
primary culture
2
E-GEOD-2450, E-GEOD-1657
YCC10
1
E-GEOD-15460
MCIXC
1
E-MTAB-37
primary pancreatic ductal adenocarcinoma
1
E-MEXP-2826
180 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-20677, E-GEOD-13987, E-GEOD-21750, E-GEOD-2822, ... (26 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-TABM-145
epithelial cell
1
2
E-MEXP-2034, E-GEOD-10797, E-GEOD-4483
leydig cell
1
E-MTAB-25
plasma cell
1
E-MEXP-2360
epidermal keratinocyte
1
E-GEOD-2822
platelet
1
E-GEOD-2006
41 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-2069, E-TABM-15, E-GEOD-22148, ... (37 experiments)

Factor Value U/D Experiments
neuroblastoma
2
E-MTAB-62, E-MTAB-37
cervical carcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MTAB-37, E-MEXP-2034
cancerous
1
E-TABM-15
hereditary leiomyomatosis and renal cell cancer
1
E-MTAB-62
Emery-Dreifuss muscular dystrophy
1
E-MTAB-62
116 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-5258, E-GEOD-15205, E-GEOD-3720, E-GEOD-5099, ... (13 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-3284, E-GEOD-995
none
2
E-GEOD-412, E-GEOD-995
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
nocodazole
1
E-GEOD-571
unknown
1
E-GEOD-7307
4,5-dianilinophthalimide
1
1
E-GEOD-5258
17 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-108, E-GEOD-6431, E-MEXP-2340

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-GEOD-2292, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-6432, E-MEXP-2657, E-MEXP-1446

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-666, E-GEOD-19519, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2508, E-GEOD-2466, E-GEOD-22541

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Vehicle
studied in E-GEOD-5258

Processing time: 0.278 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM